narmac, thanks for another great find and post. So I wonder where Don is flitting about in the midst of all of this action?

I read a couple of days ago how the TSX has been basically flat for the start of the year while the NASDAQ and other USA indexes are flying. Where does RVX trade - TSX! I need say no more!

Having re-read the last 40 posts it seems that there is a fair bit of consensus that there is one central problem dragging down the perceived value of this company and it is not the science. It is Don.

Where are we headed on the business side? Nobody knows but the recent pattern seems as follows;

1. June 20th, 2017 - $10 m raised with equity units consisting of 1 share and 1 purchase warrant at $1.80. Eastern - 1.7 million units. Hepalink - $1.3 million units. Bloom and Burton - $2.6 million units.
2. Sept 5th, 2017 - Efung of Shenzhen - $4.5 m raised consisting of 3 million equity units at a price of $1.50 consisting of 3 million shares and 1.5 million warrants.
3. Oct 24, 2017 - Hepalink - $8.0 raised for Hepalink USA was granted a right of first refusal in connection with the licensing of the right to develop, manufacture and commercialize pharmaceutical products containing RVX-208 (apabetalone) in the United States (the US Licensing Rights) until April 15, 2019
4. Dec 4th, 2017 - Hepalink. $87 m raised consisting of 60.6 million equity units and 5 million warrants at a price of $1.44.
5. Jan 8, 2018 - RVX announces deal for Medison of Isreal to market apabetalone in Israel at a cost of $0.0.

It is very difficult for me to imagine all of this great science and continuous scientific progress and a very hot USA investment market and here we have Don working his way to the bottom to practically give away the company. It is unimaginable and frustrating.

narmac, I'm beginning to believe your Eastern hypothesis. There have been various discussions about the costs of funding the balance of BoM but this is difficult because we don't even know if the trial will be boosted to 3600. Plus there will be  costs related to other trials that are now lagging behind. Don could get funding in dilutive and precident setting (race to the bottom) financings. With the pattern he is establishing perhaps Eastern could add to it's position at something less than $1.44. We know the burn rate at $3.3 million/month and we know the best case scenario for BoM is top lines at the end of Q4 2018. I'm not going to do the math because someone will flame me.

Back to Eastern, when I first started reading posts about RVX years ago I remember reading posts about Dr Wong having a very strong relationship with Ken Dart at Eastern. There were a number of such posts over the years. I also remember the post about Ken Dart telling Dr Wong that he is prepared to take apabetalone through to the finish. If he does come back in it will be a very positive signal for a few reasons;

1. It implies Dart has not abandoned biotech even afer shuttering his California division.
2. He still has confidence in the science of Dr Wong.

Who knows. Not me. I'm still confident about the science after reading through results from previous trials and I still believe that apabetalone is unique in meeting unmet medical needs and I am still hoping that this is break through science. If this drug becomes a showcase for epigenetic approaches to science it will rock the medical and scientific world and break open entirely new approaches to disease.

GLTA

Toinv